Skip to content
Home / News |

Viveve Medical Stock Jumps After Approval To Expand Manufacturing Capacity

Viveve medical
Sam Boughedda

Medical technology company Viveve Medical (NASDAQ: VIVE) said on Thursday that it has received 501(k) clearance from the US Food and Drug Administration to expand its manufacturing capacity for its consumable treatment tips. 

The expansion will allow the company to strengthen its supply chain to meet market demand and reduce its manufacturing costs. 

The treatment tips are used with Viveve’s Cryogen-cooled Monopolar Radiofrequency technology. 

X testing X
WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
5.0
Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

“We are pleased that the FDA has approved the expansion of our consumable treatment tip manufacturing capabilities. In addition to significant reductions in tip manufacturing costs, the expansion strengthens our supply chain, reduces manufacturing risk, and positions us to support increases in treatment tip demand and utilization,” said Viveve’s CEO, Scott Durbin.

Viveve shares rose premarket and are currently trading 12.71% higher after the opening bell at $5.41. Wednesday’s closing price was $4.80. 

PEOPLE WHO READ THIS ALSO VIEWED:

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.